THERAMEX
20.3.2023 17:29:26 CET | Business Wire | Press release
Theramex, a leading global speciality pharmaceutical company dedicated to women’s health, has entered into an exclusive licensing agreement with Radius Health, Inc., for the rights to commercialise ELADYNOS® (abaloparatide), a novel bone forming agent indicated for the treatment of osteoporosis in postmenopausal women at increased risk of fractures.
Theramex will commercialise and distribute ELADYNOS® on an exclusive basis in the European Economic Area, the United Kingdom, Australia and Brazil.
“Theramex has again shown its commitment to women and the care and good management of bone health, by adding this important product to our Osteoporosis franchise. We are delighted to be entering into this partnership with Radius, building on our expanding portfolio and aligning missions to reduce fracture risks for many postmenopausal women suffering from osteoporosis.” - Rob Stewart, CEO of Theramex
“We are thrilled to have Theramex bring abaloparatide to postmenopausal women in Europe who could benefit from this impactful treatment. Our aligned, strategic vision of bringing effective solutions to the right patient gives us unwavering confidence in this partnership. We look forward to seeing the continued global expansion of abaloparatide to patients with osteoporosis worldwide.” - Scott Briggs, CEO of Radius
About Theramex
Theramex is a leading global speciality pharmaceutical company dedicated to women and their health. Theramex supports women at different stages of their lives by providing a broad portfolio of innovative and established brands covering contraception, fertility, menopause, and osteoporosis. Theramex’s commitment is to listen to and understand its patients, serve their needs and offer healthcare solutions to help improve their lives. Theramex’s vision is to be a lifetime partner for women and the healthcare professionals who treat them by providing patient-focused and effective solutions that care for and support women through different stages of their life.
www.theramex.com
About Radius
Radius is a global biopharmaceutical company focused on addressing unmet medical needs in the areas of bone health and oncology. Radius’ lead product, TYMLOS® (abaloparatide) injection, was approved by the U.S. Food and Drug Administration in April 2017 for the treatment of postmenopausal women with osteoporosis at high risk for fracture, and in December 2022 for the treatment of men with osteoporosis at high risk for fracture.
ELADYNOS®(abaloparatide) injection was approved by the European Medicines Agency for the treatment of postmenopausal women with osteoporosis at high risk for fracture defined as history of osteoporotic fracture, multiple risk factors for fracture, or patients who have failed or are intolerant to other available osteoporosis therapies. This medicine is under additional monitoring, meaning that it is monitored even more intensively than other medicines.
www.radiuspharm.com
FOR MEDIA AND INVESTORS ONLY
ELAD_HQ_PRESSR_009443 D.O.P 8/3/23
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230308005585/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Swedish Court Reschedules Publication of Judgment in PriceRunner Vs Google Antitrust Case3.6.2026 10:34:00 CEST | Press release
Klarna provides investor update Klarna Group plc (NYSE: KLAR) wishes to update investors that the Patent and Market Court in Stockholm, Sweden (Patent- och marknadsdomstolen) has postponed publication of its judgment in the antitrust damages proceedings brought by PriceRunner, a Klarna subsidiary, against Google. The Court has rescheduled publication of its judgment from 10 June to 26 June, 2026 at 11:00 CET. Important Notice The outcome of the proceedings is inherently uncertain. No assurance can be given that PriceRunner will succeed on liability or quantum. Any award would be subject to appeal by Google, to sharing arrangements with former PriceRunner shareholders and Klarna’s litigation funder, and to applicable taxation. The dollar amount of the claim should not be taken as an indication of any likely recovery. This announcement does not constitute a profit forecast. Forward-Looking Statements This press release contains forward-looking statements within the meaning of applicable
Counterfeit Cigarettes Drive EU Illicit Market Above 10% for First Time Since 20143.6.2026 10:00:00 CEST | Press release
Illicit cigarettes reached 10.3% of EU consumption in 2025 (41.8 billion), with an estimated €16.7 billion in lost tax revenuesCounterfeits now lead the illicit market - accounting for 44% of EU illicit consumption (18.3 billion), up sharply year-on-year and displacing traditional East-to-West contraband flowsWestern Europe has the highest levels of illicit consumption, with France (41.4%), Belgium (24.8%), and the Netherlands (22.1%) among the most impacted. In France alone, counterfeit volumes reached nearly 10 billion cigarettes A new study detailing the scale of the illicit cigarette trade in the European Union (EU) shows that consumption of black-market cigarettes rose more than 7% year-on-year in 2025, reaching levels not seen in over a decade, with counterfeit cigarettes playing an increasingly significant role across member states. Philip Morris International (PMI) (NYSE: PM) reiterates its call for a coordinated response to illicit trade in Europe, built on evidence-based regu
Veth Propulsion by Twin Disc Unveiled New Streamline‑CRP™ at Maritime Industry Event3.6.2026 10:00:00 CEST | Press release
Product Reveal Took Place on June 2 Veth Propulsion by Twin Disc, a global leader in marine propulsion and maneuvering solutions, unveiled a new addition to its portfolio at Maritime Industry, a leading inland shipping tradeshow in the Netherlands, on June 2. Attendees experienced the debut firsthand. The new product, Streamline‑CRP™, is a major step forward in contra‑rotating propulsion technology. It was developed to meet the demand for higher efficiency, reduced emissions and better onboard comfort. It is purpose‑built for passenger cruise vessels and ferries. Streamline‑CRP delivers superior hydrodynamic performance, even in demanding, shallow‑water conditions. Streamline‑CRP is a next-generation azimuth thruster. It builds on Veth Propulsion’s long experience designing and making advanced propulsion systems. “Customers across the marine industry are demanding solutions that deliver both performance and efficiency,” said Bastiaan van Zuijlekom, Managing Director of Veth Propulsion.
Live Story Expands Into Europe’s Most Innovation-Driven Markets Amid Growing Demand for Agile Digital Experiences3.6.2026 10:00:00 CEST | Press release
Live Story, a no-code Frontend Creative Platform, is accelerating its international expansion with a strategic focus on the United Kingdom, Ireland, and the Nordics, following strong growth across its domestic markets in Italy and Switzerland, where the company doubled its ARR (Annual Recurring Revenues) in the first half of the year compared to the end of 2025. The platform enables brands to design, manage, and publish enterprise-grade digital experiences independently from development timelines, dramatically reducing time-to-market through a new “design-to-market” approach. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260603844284/en/ Live Story is a Milan-based no-code frontend creative platform The expansion reflects a strong alignment between Live Story’s vision and some of Europe’s most innovation-driven markets. The UK, Ireland, and Nordics are home to globally recognised fashion, lifestyle, and consumer brands, as
Coolbrook Appoints Veli-Matti Mattila as Chairman to Support the Next Phase of Industrial Scale-Up3.6.2026 08:00:00 CEST | Press release
Coolbrook, a transformational technology company dedicated to decarbonising heavy industry and industrial processes, has appointed renowned Finnish business leader Veli-Matti Mattila as Chairman of the Board effective immediately. Mattila brings decades of international leadership experience and board expertise to support Coolbrook’s next phase of commercial growth, industrial execution, and global scale-up. Veli-Matti Mattila is one of Finland’s most experienced technology business leaders, having served as CEO of Elisa Corporation from 2003 to 2024, following a long international career at Ericsson, where he held several senior leadership roles, including President of Ericsson Finland and COO & Deputy Head of Market Unit, Nordic & Baltic. He also spent four years in the U.S. and a period of time in Switzerland during his stint at Ericsson. He currently serves as Chairman of Orion Corporation and Enento Group, and has previously chaired Confederation of Finnish Industries (EK) and has
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom